Home Antibody All anti-ELOVL5 antibodies
Anti-ELOVL5 GAT Antibody Polyclonal
Generated by Genomic Immunization
Also for ELOVL5 (NM_021814)
|DNA immunization. This antibody is specific for the C Terminus Region of the target protein.|
||WB: 1:5000-1:20000; ELISA: 1:100-1:2000; IHC: 1:10-1:2000; IHC-P 1:10-1:2000
|20 mM Potassium Phosphate, 150 mM Sodium Chloride, pH 7.0|
|The fragment used for DNA immunization was expressed in E.coli and the purified protein fragment was used for affinity purification of the antibody.
|This antibody was generated by SDIX's Genomic Antibody Technology ® (GAT). Learn about GAT
|Homo sapiens ELOVL fatty acid elongase 5 (ELOVL5), transcript variant 1|
|dJ483K16.1; HELO1; RP3-483K16.1|
|ELOVL5 plays a role in elongation of long-chain polyunsaturated fatty acids (Leonard et al., 2000)|
* Shipping is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
Western Blot: ELOVL5 Antibody - Samples: Lane 1, Marker: 250, 130, 95, 72, 55, 36, 28, 17, 11 Lane 2, RT-4 Lane 3, U-251MG sp Lane 4, Human Plasma Lane 5, Liver Lane 6, Tonsil , Target weight: 35, 10 (splice variants) Validation score: 2 Validation description: Supportive - Band of predicted size in kDa (+/-20%) with additional bands present.
Immunohistochemistry: ELOVL5 Antibody - Most normal and malignant tissues exhibited moderate cytoplasmic and/or nuclear immunoreactivity. Strong staining was for example observed in Leydig cells, the prostate, seminal vesicles and most parts of the intestine. Some tumor types displayed strong immunoreactivity e.g. breast, colo-rectal and lung cancers. In contrast to the normal bile duct cells, which were negative, showed the cholangiocarcinomas generally moderate cytoplasmic staining. The renal cancers and most malignant lymphomas were weakly stained or negative. Image and statement courtesy of the Human Protein Atlas (HPA).